S. More

发表

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study

K. Prabhash, V. Noronha, V. Patil, 2018, ecancermedicalscience.

Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial

A. Mahajan, N. Mummudi, K. Prabhash, 2022, Esophagus.

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, Chemotherapy research and practice.

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings

A. Mahajan, K. Prabhash, V. Noronha, 2021, Ecancermedicalscience.

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

A. Dutt, Rajiv Kumar, A. Mahajan, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.

Rajiv Ranjan Kumar, K. Prabhash, V. Noronha, 2022, Clinical lung cancer.

Oral metronomic chemotherapy after definitive chemoradiation in esophageal squamous cell carcinoma: a randomized clinical trial

A. Mahajan, N. Mummudi, K. Prabhash, 2022, Esophagus.

Phase III randomized trial comparing intravenous to oral iron in patients with cancer‐related iron deficiency anemia not on erythropoiesis stimulating agents

K. Prabhash, Sudeep Gupta, V. Noronha, 2018, Asia-Pacific journal of clinical oncology.

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

S. Kannan, A. Mahajan, A. Bhattacharjee, 2019, EClinicalMedicine.

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, Ecancermedicalscience.

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2019, Oncotarget.

Tyrosine Kinase Inhibitor versus Physician Choice Chemotherapy in Second-Line Epidermal Growth Factor Receptor Mutation Non-Small Cell Lung Cancer: Post hoc Analysis of Randomized Control Trial

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2018, Indian Journal of Medical and Paediatric Oncology.

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2017, ESMO Open.

Audit of screen failure in 15 randomised studies from a low and middle-income country

K. Prabhash, V. Noronha, V. Patil, 2022, Ecancermedicalscience.

Reasons for Initiation of Areca Nut and Related Products in Patients with Oral Submucous Fibrosis within an Endemic Area in Gujarat, India

N. Johnson, S. More, N. Rao, 2020, Substance use & misuse.

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Rajiv Kumar, A. Mahajan, A. Bhattacharjee, 2018, Lung India : official organ of Indian Chest Society.

Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C).

A. Dutt, Rajiv Kumar, A. Mahajan, 2019, Journal of Clinical Oncology.

Dexamethasone and exercise for cancer-related fatigue: A phase III randomized controlled trial.

K. Prabhash, V. Noronha, V. Patil, 2023, Journal of Clinical Oncology.

Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight years

S. Goud, S. More, Ajay Singh, 2024, Cancer Research, Statistics, and Treatment.